Haemonetics Co. (NYSE:HAE) Shares Bought by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans raised its position in Haemonetics Co. (NYSE:HAE) by 14.9% in the 4th quarter, Holdings Channel reports. The fund owned 1,264,294 shares of the medical instruments supplier’s stock after purchasing an additional 164,111 shares during the period. Thrivent Financial for Lutherans’ holdings in Haemonetics were worth $98,716,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Global Alpha Capital Management Ltd. acquired a new stake in Haemonetics in the third quarter valued at approximately $806,000. Loomis Sayles & Co. L P boosted its stake in shares of Haemonetics by 8.1% during the 3rd quarter. Loomis Sayles & Co. L P now owns 163,856 shares of the medical instruments supplier’s stock valued at $13,171,000 after buying an additional 12,310 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Haemonetics by 174.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock valued at $1,362,000 after buying an additional 10,774 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in shares of Haemonetics by 10.9% during the 3rd quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier’s stock valued at $66,206,000 after buying an additional 80,783 shares during the last quarter. Finally, Boston Trust Walden Corp boosted its stake in shares of Haemonetics by 13.1% during the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock valued at $71,500,000 after buying an additional 106,114 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Performance

Shares of HAE opened at $64.69 on Wednesday. The business’s fifty day moving average price is $68.08 and its 200 day moving average price is $75.26. Haemonetics Co. has a 12-month low of $58.80 and a 12-month high of $97.97. The stock has a market capitalization of $3.25 billion, a PE ratio of 25.47, a price-to-earnings-growth ratio of 1.11 and a beta of 0.43. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Equities research analysts forecast that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. assumed coverage on Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 target price for the company. Raymond James reiterated a “strong-buy” rating and set a $115.00 target price (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Needham & Company LLC reduced their target price on Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a research note on Tuesday. Barrington Research reduced their target price on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Finally, StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.